The clinicopathological features and survival of Castleman disease: a multicenter Turkish study

Basit Öğe Kaydı
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridYılmaz, Fatma/0000-0001-6112-3950
dc.authoridYILMAZ, Farise/0000-0001-8136-513X
dc.authoridDogan, Abdulahad/0000-0002-5438-8560;
dc.authorwosidYILDIZ, Jale/JUV-0320-2023
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidYılmaz, Fatma/ACX-9470-2022
dc.authorwosidAlbayrak, Murat/JUU-5382-2023
dc.authorwosidYILMAZ, Farise/KGL-6445-2024
dc.authorwosidUlas, Turgay TU/A-6050-2018
dc.authorwosidDogan, Abdulahad/ACO-8746-2022
dc.contributor.authorYildiz, J.
dc.contributor.authorBagci, M.
dc.contributor.authorSayin, S.
dc.contributor.authorKaya, A.
dc.contributor.authorYilmaz, F.
dc.contributor.authorEkinci, O.
dc.contributor.authorDal, M. S.
dc.date.accessioned2024-08-04T20:51:45Z
dc.date.available2024-08-04T20:51:45Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractOBJECTIVE: In this study, we aimed to investigate the clinicopathological features and survival of CD, which is quite rare and has many unknowns. PATIENTS AND METHODS: This study was conducted by retrospectively evaluating patients diagnosed with CD in six different centers in Turkey. RESULTS: The median age of 33 patients included in the study was 49 and 51.5% (n = 17) of these patients were women. 18 (54.5%) patients were in the hyaline vascular subtype and most of the patients were UCD (n = 20, 60.6%). The most common involvement region was head and neck (n = 19, 57.5%). The UCD group was younger than the MCD group (p=0.027). Visceral lymph node involvement was higher in MCD than in UCD (p=0.001). Similarly, it was observed that there was more hepatomegaly (p=0.035) and splenomegaly (p=0.013) in the MCD group. During the median 19.5 months follow-up period, there were no patients who died. CONCLUSIONS: It was observed that UCD and MCD are different clinical entities. Promising survival times can be achieved with surgical and systemic treatments in both subtypes of this extremely rare disease. However, this re- suit should be supported by well-designed prospective comprehensive studies.en_US
dc.identifier.endpage1137en_US
dc.identifier.issn1128-3602
dc.identifier.issue4en_US
dc.identifier.pmid35253168en_US
dc.identifier.scopus2-s2.0-85125881550en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1131en_US
dc.identifier.urihttps://hdl.handle.net/11616/100516
dc.identifier.volume26en_US
dc.identifier.wosWOS:000763332500012en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCDen_US
dc.subjectUnicentric Castleman diseaseen_US
dc.subjectMulticentric Castleman diseaseen_US
dc.subjectHyaline vascularen_US
dc.titleThe clinicopathological features and survival of Castleman disease: a multicenter Turkish studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu